Restoring Trust After a Drug Safety Controversy
Mid-Size Pharmaceutical CompanyCrisis Communications · Public Relations · Video Production
- The challenge
- “Adverse-event reports and a class-action filing triggered viral backlash and a 15% one-week stock drop”
Headline results
- 45 daysTo Sentiment Recovery
- 82%Physician Confidence
Overview
A mid-size pharmaceutical company faced sensationalized media coverage of adverse-event reports linked to a flagship prescription product. With a class-action filing accelerating social media backlash and a 15% one-week stock decline, the company needed to stabilize physician sentiment, reassure patients and investors, and reset the narrative without inflaming litigation exposure.
The situation
Adverse-event reports surfaced through a small but vocal patient advocacy group and were quickly amplified by mainstream outlets. Within days, a class-action complaint had been filed and prescribing sentiment among physicians was eroding. Internal counsel limited what could be said publicly, but every day of silence was being interpreted as concealment by patients, prescribers, and Wall Street.
Our approach
-
Step 1
Tiered Stakeholder Messaging
We built separate, coordinated message sets for patients, prescribing physicians, investors, and regulators—each addressing the specific concern that audience was actually voicing, instead of a single all-purpose corporate statement.
-
Step 2
Chief Medical Officer Visibility
We placed the CMO on credibility-building broadcast and trade outlets where clinical data could be presented directly to physicians, rather than fighting the narrative on the entertainment-news circuit.
-
Step 3
Long-Form Podcast Strategy
We booked the CMO and patient advocates on physician-focused and patient-advocacy podcasts to counter sensationalized clips with the kind of nuanced, evidence-based conversation that 90-second segments cannot accommodate.
-
Step 4
Owned Video Library
We produced a transparent 'Behind the Science' series with the R&D team, patient testimonials, and a physician Q&A format—all distributed through company channels and paid social to ensure the brand controlled the visual narrative.
Execution
- Stood up tiered messaging framework and CMO talking points within 72 hours, fully cleared by legal
- Placed the CMO on 18 national broadcast segments over the campaign window
- Booked 15 health and physician-targeted podcasts to drive the long-form counter-narrative
- Produced and released the 'Behind the Science' video series across owned channels and paid distribution
- Coordinated daily media monitoring and weekly sentiment briefings for the executive team and board
Results
-
Sentiment shifted in 45 days
Aggregate media tone moved from net negative to net neutral within 45 days, with several outlets running follow-up stories on the company's clinical transparency.
-
18
national broadcast placements
CMO appearances in tier-one health and business broadcasts that the company had not previously reached, creating a referenceable evidence base for prescribers.
-
Physician confidence to 82%
Independent physician sentiment tracking recovered from a low of 54% to 82% over the campaign window, restoring prescribing momentum.
-
Stock recovered in 90 days
Share price returned to pre-controversy levels within 90 days, and patient inquiries through the company portal grew 65% as trust signals shifted.
What we learned
Drug-safety stories rarely turn on the underlying science alone—they turn on whether the company is perceived as transparent. The legal instinct to say nothing is almost always wrong; the strategic answer is to say a great deal, very precisely, to the audiences who actually move outcomes. Going long-form with physicians and putting clinical leaders on the record was what shifted prescribing sentiment. The media tone followed.
Facing a similar situation?
Every engagement starts with a confidential conversation about what you're facing and what success looks like.
In a crisis right now? Call (844) 460-5884